Thinzar Min1,2, Sarah L Prior3, Rachel Churm3, Gareth Dunseath3, Jonathan D Barry4, Jeffrey W Stephens3,4,5. 1. Diabetes Research Group, Swansea University Medical School, Grove Building, Singleton Campus, Swansea, SA2 8PP, UK. thinzar.min@swansea.ac.uk. 2. Department of Diabetes and Endocrinology, Neath Port Tablot Hospital, Swansea Bay UHB, Port Talbot, SA12 7BX, UK. thinzar.min@swansea.ac.uk. 3. Diabetes Research Group, Swansea University Medical School, Grove Building, Singleton Campus, Swansea, SA2 8PP, UK. 4. Welsh Institute of Metabolic & Obesity Surgery, Morriston Hospital, Swansea Bay UHB, Swansea, SA6 6NL, UK. 5. Department of Diabetes and Endocrinology, Morriston Hospital, Swansea Bay UHB, Swansea, SA6 6NL, UK.
Abstract
INTRODUCTION: There is limited literature available on the long-term effect of bariatric surgery especially laparoscopic sleeve gastrectomy (LSG) on the incretin hormone response. AIM: Our primary aim was to investigate changes in glucose metabolism and incretin hormone responses in participants with impaired glucose regulation approximately 4 years after LSG. The secondary aim was to examine the long-term incretin hormone changes of biliopancreatic diversion (BPD). METHOD: A non-randomised prospective study comprising of 10 participants undergoing LSG and 6 participants undergoing BPD. Serial measurements of glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were performed during an oral glucose tolerance test pre-operatively and 1 month, 6 months and at approximately 4-7 years post-operatively. Area under the curve (AUC) was examined at 60 and 120 min. RESULTS: In the LSG group, a significant reduction in 2-h plasma glucose (2 h PG), HbA1c and HOMA-IR was observed at 4 years. Compared with pre-operative levels, significant increases in post-glucose GLP-1 secretion were observed at 1 and 6 months, but not maintained at 4 years. A linear increase was seen in post-glucose GIP response at 1 month and 6 months and 4 years. Within the BPD group, a reduction in HbA1c along with an increase GLP-1 response was observed at 7 years. CONCLUSION: An increase in GLP-1 response was not preserved at 4 years, but a significant increase in GIP response was observed along with improved glycaemic control following LSG.
INTRODUCTION: There is limited literature available on the long-term effect of bariatric surgery especially laparoscopic sleeve gastrectomy (LSG) on the incretin hormone response. AIM: Our primary aim was to investigate changes in glucose metabolism and incretin hormone responses in participants with impaired glucose regulation approximately 4 years after LSG. The secondary aim was to examine the long-term incretin hormone changes of biliopancreatic diversion (BPD). METHOD: A non-randomised prospective study comprising of 10 participants undergoing LSG and 6 participants undergoing BPD. Serial measurements of glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were performed during an oral glucose tolerance test pre-operatively and 1 month, 6 months and at approximately 4-7 years post-operatively. Area under the curve (AUC) was examined at 60 and 120 min. RESULTS: In the LSG group, a significant reduction in 2-h plasma glucose (2 h PG), HbA1c and HOMA-IR was observed at 4 years. Compared with pre-operative levels, significant increases in post-glucoseGLP-1 secretion were observed at 1 and 6 months, but not maintained at 4 years. A linear increase was seen in post-glucoseGIP response at 1 month and 6 months and 4 years. Within the BPD group, a reduction in HbA1c along with an increase GLP-1 response was observed at 7 years. CONCLUSION: An increase in GLP-1 response was not preserved at 4 years, but a significant increase in GIP response was observed along with improved glycaemic control following LSG.
Authors: Chinmay S Marathe; Michael Horowitz; Laurence G Trahair; Judith M Wishart; Michelle Bound; Kylie Lange; Christopher K Rayner; Karen L Jones Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Elisenda Climent; David Benaiges; Juana A Flores-Le Roux; Jose M Ramón; Juan Pedro-Botet; Albert Goday Journal: Surg Obes Relat Dis Date: 2018-05-19 Impact factor: 4.734
Authors: Andrew D Van Osdol; Brandon T Grover; Andrew J Borgert; Kara J Kallies; Shanu N Kothari Journal: Surg Obes Relat Dis Date: 2016-10-01 Impact factor: 4.734
Authors: G Nosso; E Griffo; M Cotugno; G Saldalamacchia; R Lupoli; G Pacini; G Riccardi; L Angrisani; B Capaldo Journal: Horm Metab Res Date: 2016-01-20 Impact factor: 2.936
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino Journal: Lancet Date: 2015-09-05 Impact factor: 79.321
Authors: Akhila Mallipedhi; Sarah L Prior; Jonathan D Barry; Scott Caplin; John N Baxter; Jeffrey W Stephens Journal: Surg Obes Relat Dis Date: 2014-03-12 Impact factor: 4.734
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; Sofie Ahlin; Johanna Andersson-Assarsson; Åsa Anveden; Claude Bouchard; Björn Carlsson; Kristjan Karason; Hans Lönroth; Ingmar Näslund; Elisabeth Sjöström; Magdalena Taube; Hans Wedel; Per-Arne Svensson; Kajsa Sjöholm; Lena M S Carlsson Journal: JAMA Date: 2014-06-11 Impact factor: 56.272